Doxorubicin enhances nucleosome turnover around promoters

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Doxorubicin is a widely used anthracycline anticancer drug.
• Its mechanism involves DNA intercalation and causing double-strand breaks.
• The effect of doxorubicin on general chromatin properties, specifically nucleosome dynamics, remains largely unknown.

Purpose of the Study:

• To investigate the impact of doxorubicin on chromatin dynamics.
• To examine nucleosome turnover rates in response to doxorubicin treatment.
• To explore the relationship between doxorubicin, gene expression, and chromatin properties.

Main Methods:

• Utilized a metabolic labeling strategy to directly measure nucleosome turnover.
• Studied squamous cell carcinoma cell lines from genetically defined mice.
• Assessed doxorubicin's effects in wild-type cells and cells lacking p53 or ATM.

Main Results:

• Doxorubicin significantly enhances nucleosome turnover around gene promoters.
• Nucleosome turnover correlates positively with gene expression levels.
• This enhancement is time-dependent and occurs independently of p53 and ATM, suggesting DNA damage checkpoint independence.
• Aclarubicin, another anthracycline, exhibits similar effects.

Conclusions:

• Anthracycline intercalation promotes nucleosome turnover at gene promoters.
• This effect is likely mediated by alterations in DNA topology.
• Findings suggest potential implications for understanding cancer chemotherapy mechanisms and cell killing.